[{"address1": "1 Controls Drive", "city": "Shelton", "state": "CT", "zip": "06484", "country": "United States", "phone": "203 937 6137", "fax": "203 859 5095", "website": "https://www.nanoviricides.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "NanoViricides, Inc., a clinical stage nano-biopharmaceutical company, discovers, develops, and commercializes drugs for the treatment of viral infections. The company's product portfolio includes NV-CoV-2, nanoviricide drug which is in phase 1a/1b clinical trails for the treatment of Covid; and NV-CoV-2 Oral Syrup, and NV-CoV-2 Oral Gummies, a semi-solid fixed-dose form which are in phase 1a/1b human clinical trials for enabling body-weight-based dose titration as is required for pediatric cases. It also offers NV-CoV-2 Solution for injection, infusion, and inhalation to treat severe cases that are not yet hospitalized would be best performed by an injection; and injectable solution can be delivered directly into the lungs as a fog created using standard portable battery operated nebulizer devices which enables action at the most important site of infection by a respiratory virus, such as coronaviruses, RSV, influenzas, human meta-pneumovirus, certain adenoviruses, and other infections, that can lead to severe pneumonia. In addition, the company provides Nanoviricide, a biomimetic platform technology designed to attack enveloped virus particles to deliver anti-viral payload into infected cells sparing uninfected cells to block replication cycle without toxicity. NanoViricides, Inc. was incorporated in 2005 and is headquartered in Shelton, Connecticut.", "fullTimeEmployees": 7, "maxAge": 86400, "priceHint": 4, "previousClose": 2.03, "open": 2.02, "dayLow": 1.78, "dayHigh": 2.03, "regularMarketPreviousClose": 2.03, "regularMarketOpen": 2.02, "regularMarketDayLow": 1.78, "regularMarketDayHigh": 2.03, "beta": 0.943, "forwardPE": -2.0222223, "volume": 151347, "regularMarketVolume": 151347, "averageVolume": 238785, "averageVolume10days": 490810, "averageDailyVolume10Day": 490810, "bidSize": 1100, "askSize": 800, "marketCap": 21501480, "fiftyTwoWeekLow": 1.0, "fiftyTwoWeekHigh": 3.59, "fiftyDayAverage": 1.8486, "twoHundredDayAverage": 1.34845, "currency": "USD", "enterpriseValue": 18244248, "floatShares": 11269493, "sharesOutstanding": 11814000, "sharesShort": 126429, "sharesShortPriorMonth": 112123, "sharesShortPreviousMonthDate": 1713139200, "dateShortInterest": 1715731200, "sharesPercentSharesOut": 0.0107, "heldPercentInsiders": 0.046040002, "heldPercentInstitutions": 0.10103, "shortRatio": 0.64, "shortPercentOfFloat": 0.0112, "impliedSharesOutstanding": 11814000, "bookValue": 0.902, "priceToBook": 2.0177383, "lastFiscalYearEnd": 1688083200, "nextFiscalYearEnd": 1719705600, "mostRecentQuarter": 1711843200, "netIncomeToCommon": -9508152, "trailingEps": -0.82, "forwardEps": -0.9, "lastSplitFactor": "1:20", "lastSplitDate": 1569283200, "enterpriseToEbitda": -2.017, "52WeekChange": 0.6545454, "SandP52WeekChange": 0.26238096, "exchange": "ASE", "quoteType": "EQUITY", "symbol": "NNVC", "underlyingSymbol": "NNVC", "shortName": "NanoViricides, Inc.", "longName": "NanoViricides, Inc.", "firstTradeDateEpochUtc": 1130333400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "9f404998-ae7c-3809-9925-75444d9a2872", "messageBoardId": "finmb_22594191", "gmtOffSetMilliseconds": -14400000, "currentPrice": 1.82, "targetHighPrice": 6.5, "targetLowPrice": 6.5, "targetMeanPrice": 6.5, "targetMedianPrice": 6.5, "recommendationMean": 2.0, "recommendationKey": "buy", "numberOfAnalystOpinions": 1, "totalCash": 3257240, "totalCashPerShare": 0.276, "ebitda": -9043830, "quickRatio": 4.005, "currentRatio": 4.323, "returnOnAssets": -0.40780997, "returnOnEquity": -0.65847, "freeCashflow": -4749467, "operatingCashflow": -6332755, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-06-24"}]